CRISPR Therapeutics CRSP
$39.10 +$0.17 (+0.44%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $39.50 +1.02%
Open$38.18
Prev close$38.93
Day range$38.15 – $40.17
Volume3.32M
Market cap$3.79B
P/E (TTM)–
Dividend yield–
CRSP Stock News
Headlines matching CRISPR Therapeutics or the CRSP ticker, most recent first.
- Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Raises Target Price to $55 Positive
- BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82 Negative
- A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $60 to $110
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
- Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76
- H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
- Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
- William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
- Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $55
- BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $83
- Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $110
- Morgan Stanley Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $60
- Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
- Morgan Stanley Upgrades CRISPR Therapeutics(CRSP.US) to Hold Rating, Raises Target Price to $60 Positive
- Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $75
No comments yet — be the first to weigh in on CRSP.
Sign in to join the discussion.